Comparison of the 24-Hour Intraocular Pressure-Lowering Effects of Latanoprost and Dorzolamide/Timolol Fixed Combination after 2 and 6 Months of Treatment

Ophthalmology

Volumn 115, Issue 1, 2008, Pages

  Konstas, Anastasios G P ^a   Kozobolis, Vassilios P ^b   Tsironi, Sevasti ^a   Makridaki, Irene ^a   Efremova, Rallitsa ^a   Stewart, William C ^c,d  

^a Glaucoma Unit   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^c UNIVERSITY OF SOUTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d University of South Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIMATOPROST; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; TIMOLOL; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG WITHDRAWAL; DRY EYE; DYSPNEA; EVENING DOSAGE; EYE BURNING; FEMALE; FOREIGN BODY; HEADACHE; HUMAN; HYPERTRICHOSIS; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; IRIS HYPERCHROMIA; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PUNCTATE KERATITIS; RANDOMIZED CONTROLLED TRIAL; TASTE DISORDER; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 37349086094     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ophtha.2007.03.007     Document Type: Article

References (24)

1. Alm A., Stjernschantz J., and Scandinavian Latanoprost Study Group. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning: a comparison with timolol. Ophthalmology 102 (1995) 1743-1752
2. Camras C.B., and United States Latanoprost Study Group. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. Ophthalmology 103 (1996) 138-147
3. Watson P., Stjernschantz J., and Latanoprost Study Group. A six-month, randomized, double-masked study comparing latanoprost with timolol in open-angle glaucoma and ocular hypertension. Ophthalmology 103 (1996) 126-137
4. Smith S.L., Pruitt C.A., Sine C.S., et al. The use of latanoprost 0.005% once daily to simplify medical therapy in patients with primary open-angle glaucoma or ocular hypertension. Acta Ophthalmol Scand 77 (1999) 189-192
5. Clineschmidt C.M., Williams R.D., Snyder E., and Adamsons I.A. A randomized trial in patients inadequately controlled on timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Ophthalmology 106 suppl (1999) 17-24
6. Hutzelmann J., Owens S., Shedden A., et al. Comparison of the safety and efficacy of the fixed combination of dorzolamide/timolol and the concomitant administration of dorzolamide and timolol: a clinical equivalence study. Br J Ophthalmol 82 (1998) 1249-1253
7. Boyle J.E., Ghosh K., Gieser D.K., and Adamsons I.A. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol or dorzolamide. Ophthalmology 106 (1999) 10-16
8. Fechtner R.D., Airaksinen P.J., Getson A.J., et al. Efficacy and tolerability of the dorzolamide 2%/timolol 0.5% combination (COSOPT) versus 0.005% (XALATAN) in the treatment of ocular hypertension or glaucoma: results from two randomized clinical trials. Acta Ophthalmol Scand 82 (2004) 42-48
9. Konstas A.G., Papapanos P., Tersis I., et al. Twenty-four-hour diurnal curve comparison of commercially available latanoprost 0.005% versus the timolol and dorzolamide fixed combination. Ophthalmology 110 (2003) 1357-1360
10. Orzalesi N., Rossetti L., Bottoli A., et al. The effect of latanoprost, brimonidine, and a fixed combination of timolol and dorzolamide on circadian intraocular pressure in patients with glaucoma or ocular hypertension. Arch Ophthalmol 121 (2003) 453-457
11. Konstas A.G., Mantziris D.A., and Stewart W.C. Diurnal intraocular pressure in untreated exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115 (1997) 182-185
12. Konstas A.G., Mantziris D.A., Cate E.A., and Stewart W.C. Effect of timolol on the diurnal intraocular pressure in exfoliation and primary open-angle glaucoma. Arch Ophthalmol 115 (1997) 975-979
13. Book S.A. Essentials of Statistics (1978), McGraw-Hill, New York 117-22, 205-15.
14. Konstas A.G., Maltezos A.C., Gandi S., et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol 128 (1999) 15-20
15. Mundorf T.K., Cate E.A., Sine C.S., et al. The safety and efficacy of switching timolol maleate 0.5% solution to timolol hemihydrate 0.5% solution given twice daily. J Ocul Pharmacol Ther 14 (1998) 129-135
16. Duff G.R. A double-masked crossover study comparing the effects of carteolol 1% and 2% on intra-ocular pressure. Acta Ophthalmol (Copenh) 65 (1987) 618-621
17. Stewart W.C., Day D.G., Stewart J.A., et al. The efficacy and safety of latanoprost 0.005% once daily versus brimonidine 0.2% twice daily in open-angle glaucoma or ocular hypertension. Am J Ophthalmol 131 (2001) 631-635
18. Siegel S. Nonparametric Statistics for the Behavioral Sciences (1956), McGraw-Hill, New York 63-67
19. Richter M., Krauss A.H., Woodward D.F., and Lutjen-Drecoll E. Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide. Invest Ophthalmol Vis Sci 44 (2003) 4419-4426
20. AGIS Investigators. The Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. Am J Ophthalmol 130 (2000) 429-440
21. Heijl A., Leske M.C., Bengtsson B., et al. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol Scand 81 (2003) 286-293
22. Boger III W.P. Shortterm "escape" and longterm "drift": the dissipation effects of the beta adrenergic blocking agents. Surv Ophthalmol 28 (1983) 235-242
23. Manni G., Centofanti M., Parravano M., et al. A 6-month randomized clinical trial of bimatoprost 0.03% versus the association of timolol 0.5% and latanoprost 0.005% in glaucomatous patients. Graefes Arch Clin Exp Ophthalmol 242 (2004) 767-770
24. Zimmerman T.J., Stewart W.C., and Latanoprost Axis Study Group. Intraocular pressure, safety, and quality of life in glaucoma patients switching to latanoprost from monotherapy treatments. J Ocul Pharmacol Ther 19 (2003) 405-415